aleniglipron or placebo

DRUG3 trials

Sponsors

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Conditions

Chronic Weight ManagementObesityObesity, Overweight, or Chronic Weight ManagementOverweight

Phase 2

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

CompletedNCT06693843

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsObesity, Overweight, or Chronic Weight Management

Start: 2024-10-28End: 2026-07-09Updated: 2026-08-10

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

CompletedNCT06703021

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsChronic Weight Management, Obesity, Overweight

Start: 2024-12-20End: 2026-01-12Updated: 2026-04-28

Aleniglipron Phase 2 Body Composition Study

Active, not recruitingNCT07169942

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsObesity, Overweight, or Chronic Weight Management

Start: 2025-08-15End: 2026-10-01Updated: 2026-03-03

Related Papers

Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial

Nature Medicine2026-06-05